AriBio Co., Ltd.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

AR1001 · Diabetes
AR1001 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

AriBio Co., Ltd. portfolio CI brief
AriBio Co., Ltd. pipeline updates RSS

Frequently asked questions about AriBio Co., Ltd.

What is AriBio Co., Ltd.'s pipeline?

AriBio Co., Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include AR1001.

Sector hub: All tracked pharma companies